ME-143
/ Lite Strategy
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
June 04, 2012
Marshall Edwards presents results from clinical trial of lead oncology drug candidate ME-143
(MEI Pharma, ASCO 2012)
- P1, N=15; Study ID ME-143-001; Marshall Edwards announced results from a P1 clinical trial of its lead drug candidate ME-143 in patients with solid refractory tumors; The data were presented at the ASCO Annual Meeting in Chicago; 15 pts were enrolled in escalating dose cohorts of 2.5 mg/kg, 5 mg/kg, 10 mg/kg & 20 mg/kg; SD was observed in one pt at more than 15 weeks, which is comparable to P1 studies of phenoxodiol, the Company’s first-generation NADH oxidase inhibitor, in which SD was also the best response observed; Anticipated P2 efficacy studies of ME-143 in combination with SOC chemotherapy later this year
Anticipated new P2 trial • P1 data • Oncology
June 04, 2012
Marshall Edwards presents results from clinical trial of lead oncology drug candidate ME-143
(MEI Pharma, ASCO 2012)
- P1, N=15; Study ID ME-143-001; Marshall Edwards announced results from a P1 clinical trial of its lead drug candidate ME-143 in patients with solid refractory tumors; The data were presented at the ASCO Annual Meeting in Chicago; 15 pts were enrolled in escalating dose cohorts of 2.5 mg/kg, 5 mg/kg, 10 mg/kg & 20 mg/kg; SD was observed in one pt at more than 15 weeks, which is comparable to P1 studies of phenoxodiol, the Company’s first-generation NADH oxidase inhibitor, in which SD was also the best response observed; Anticipated P2 efficacy studies of ME-143 in combination with SOC chemotherapy later this year
Anticipated new P2 trial • P1 data • Oncology
March 19, 2012
Marshall Edwards announces terms for rights offering to stockholders
(PRNewswire)
- Marshall Edwards announced that it has set the record date and pricing terms for its previously announced rights offering to existing stockholders; Company intends to use the net proceeds from the offering primarily to continue the clinical development of its two lead oncology drug candidates, ME-143 & ME-344
Financial update • Oncology
November 23, 2018
Study of Molecular Mechanism of the Interaction Between MEK1/2 and Trametinib with Docking and Molecular Dynamic Simulation.
(PubMed, Interdiscip Sci)
- "The results showed that trametinib inactivates the enzyme by bonding to a group of amino acids including Lys97/101, SER218/216, Asp208/212, and Met143/147 in MEK1/2. By bonding to the essential amino acids, trametinib inhibits the activity of the enzyme. All in all, the acquired results can be of great use in designing new inhibitors."
Journal
1 to 4
Of
4
Go to page
1